Lilly to book $790M Amylin payment in third quarter
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Dr. Craig Brater, 66, has worked at the Indianapolis-based school for 26 years, including the past 12 as dean. The school is the second largest medical school in the nation and the only one in Indiana.
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
How many times do you suppose Brian Payne heard, “Yeah, but” when he was selling the idea of a Cultural Trail?
Steve Goldsmith was one of the brightest men to run for governor of Indiana but he lacked a populist touch.
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
Student Development Co. helps college students run Textbook Painting businesses, to learn the ins and outs of entrepreneurship. Thirty students in seven states are participating this summer, including 10 student entrepreneurs in Indiana.
The Indy Warehouse Automation Expo will showcase new generation of scanners, cameras and radio frequency ID technology.
Research and development comes under pressure in an age of austerity.
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Indiana University has received the go-ahead to begin the accreditation process for new schools of public health proposed for its Bloomington and Indianapolis campuses, according to the Associated Press. University officials said the step by the independent Council on Education for Public Health kicks off an expected two-year process to create schools of public health on IU's two largest campuses. The school on the Bloomington campus will focus on rural communities. The Indianapolis school will focus on urban health and health policy, as well as on collaborative work with the IU School of Medicine.
An antipsychotic drug that Eli Lilly and Co. hoped would be an improved replacement for Zyprexa failed in a late-stage study that compared patients taking the drug to those taking a placebo. The drug, known as pomaglumetad methionil, or mGlu 2/3, showed no difference versus a placebo. A control group of patients taking another drug, risperidone, which goes by the brand name Risperdal, did show a difference. Despite the failure, Lilly said it would continue to conduct two other clinical trials of the drug. Lilly is studying pomaglumetad methionil to see whether it can work as an antipsychotic without side effects like weight gain that come with current treatments. Zyprexa, which reached peak annual sales of $5 billion, lost its U.S. and European patent protection last fall.
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General. Attorney General Greg Zoeller has filed a complaint against Allcare Dental & Dentures, which closed offices in Anderson, Avon, Evansville, Fort Wayne, Indianapolis, Mishawaka and Muncie. The complaint alleges multiple licensing violations against company President Robert Bates. The complaint says Allcare failed to reimburse patients who paid upfront for services that weren’t completed; failed to complete dental procedures in progress; didn’t provide dentures that were fabricated; and locked dentists out of their offices, rendering them unable to notify patients or transfer patient records as the law requires. Massachusetts, New Hampshire, North Dakota, Ohio and West Virginia also have taken actions against Bates’ dental licenses for similar violations. Bates has settled or been party to consent agreements with licensing boards of each of those states, according to the AG’s complaint. The Indiana State Board of Dentistry is scheduled to conduct a hearing on the complaint Oct. 5.
After six months of denying coverage for a $350 genetic test for each of three Indiana children, Indianapolis-based WellPoint Inc. reversed itself and will now pay for the tests, according to Bloomberg News. The father of the three children, Matthew Christman, has an inherited heart disease that often strikes without warning. Since December, WellPoint’s Anthem Blue Cross and Blue Shield unit had denied paying for the test, saying it was “experimental” and “not medically necessary,” according to Bloomberg. The test is made by New Jersey-based Bio-Reference Labs Inc.
Eli Lilly and Co. got a boost of confidence last week that its project to launch the first effective Alzheimer’s treatment is on the right track—though it still faces hugely long odds.
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Local government should encourage such partnerships.
We often hear that government should be run more like business.